Welcome to the e-CCO Library!

DOP062: Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: explorative IBD subgroup-analyses in Crohn's disease and ulcerative colitis from the NOR-SWITCH trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Jørgensen K.K.*1, Olsen I.C.2, Goll G.L.2, Lorentzen M.3, Bolstad N.4, Berset I.P.5, Haavardsholm E.A.2,6, Lundin K.E.6,7,8, Mørk C.9, Kvien T.K.2,6, Jahnsen J.1,6 and the Nor-Switch Study Group

Created: Wednesday, 20 February 2019, 10:36 AM
DOP062: Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: Explorative IBD subgroup-analyses in Crohn’s Disease and ulcerative colitis from the NOR-SWITCH trial
Year: 2017
Source: ECCO'17 Barcelona
Authors: Jørgensen K.
Crohn's disease, Ulcerative colitis, Infliximab, Biosimilars
Files: 1
DOP062: Malignancy and mortality in paediatric onset inflammatory bowel disease
Year: 2016
Source: ECCO'16 DOP
Authors: Joosse M.
IBD-associated cancer, mortality
Files: 1
DOP062: Malignancy and mortality in paediatric-onset inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

L. de Ridder1, M. Joosse*2, D. Turner3, D. Wilson4, S. Koletzko5, J. Martin-de-Carpi6, U. Fagerberg7, C. Spray8, M. Sladek9, R. Shaoul10, E. Roma-Giannikou11, J. Bronsky12, D. Serban13, S. Cucchiara14, G. Veres15, F. Ruemmele16, I. Hojsak17, K. Kolho18, I. Davies19, M. Aloi20, P. Lionetti21, G. Veereman-Wauters22, C. Braegger23, E. Trindade24, A. V. Wewer25, A. Hauer26, A. Levine27

Created: Friday, 22 February 2019, 9:49 AM
DOP062: The anti-MAdCAM antibody SHP647 in Crohn’s disease: Endoscopic effects of induction therapy
Year: 2018
Source: ECCO '18 Vienna
Authors:

G.R. D´Haens1*, K. Gorelick2, Y. Wang3, F. Cataldi3, W.J. Sandborn4

Created: Thursday, 21 February 2019, 9:14 AM
DOP062: The anti-MAdCAM antibody SHP647 in Crohn’s Disease: Endoscopic effects of induction therapy
Year: 2018
Source: ECCO'18 Vienna
Authors: D´Haens Geert R
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP063: Inhibition of tyrosine kinase 2 signalling ameliorates T cell transfer colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

L.C. De Vries1,2, M.E. Wildenberg1,2*, R.A. Willemze1,2, H.P. van Hamersveld1, O. Welting1, C. Verseijden1, B. Strobl3, M. Mueller3, G.R. D'Haens2, W.J. De Jonge1

Created: Thursday, 21 February 2019, 9:14 AM
DOP063: Measurement of Endoscopic Severity in a Crohn's Disease Multi-Centre Pediatric Inception Cohort: Poor correlation of SES-CD with PCDAI
Year: 2016
Source: ECCO'16 DOP
Authors: Carman N.
disease activity indices, Crohn's Disease
Files: 1
DOP063: Measurement of endoscopic severity in a Crohns disease multicentre paediatric inception cohort: poor correlation of SES-CD with Paediatric Crohns Disease Activity Index (PCDAI)
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

N. Carman*1, P. Church1, H. Huynh2, D. Mack3, K. Jacobson4, A. Otley5, J. De Bruyn6, W. El-Matery7, C. Deslandres8, M. Carroll2, E. Wine2, E. Benchimol3, J. Van Limbergen5, A. Griffiths1, T. Walters1

Created: Friday, 22 February 2019, 9:49 AM
DOP063: Serial tuberculin skin test improves the detection of latent tuberculosis infection in inflammatory bowel disease patients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Taxonera C.*1, Ponferrada A.2, Bermejo F.3, Gisbert J.P.4, Riestra S.5, Saro C.6, Cabriada J.L.7, Barreiro-de Acosta M.8, Barrio J.9, Flores E.10, Ferrer I.11, Hernandez A.12, Van Domselaar M.13, Olivares D.1, Alba C.1, Fernández-Salazar L.14, Merino O.15, Botella B.16, Ceballos D.17, Moral I.18, Peñate M.19, Algaba A.3 on behalf of the SEGURTB Study Group from GETECCU

Created: Wednesday, 20 February 2019, 10:36 AM
DOP063: Serial tuberculin skin test improves the detection of latent tuberculosis infection in Inflammatory Bowel Disease patients
Year: 2017
Source: ECCO'17 Barcelona
Authors: Taxonera C.
Crohn's disease, Ulcerative colitis, Anti-TNF agents, Thiopurines (AZA / MP), Tuberculosis
Files: 1
DOP064: Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab
Year: 2016
Source: ECCO'16 DOP
Authors: Ungar B.
anti-TNF agents, therapeutic drug monitoring
Files: 1
DOP064: Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

B. r*1, M. Yavzori1, O. Picard1, E. Fudim1, U. Kopylov1, E. Del Tedesco2, S. Paul2, Y. Chowers3, R. Eliakim1, S. Ben-Horin1, X. Roblin2

Created: Friday, 22 February 2019, 9:49 AM
DOP064: ECCO expert consensus and topical review on treatment exit strategies in Inflammatory Bowel Disease
Year: 2018
Source: ECCO'18 Vienna
Authors: Doherty Glen
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP064: ECCO expert consensus and topical review on treatment exit strategies in inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. Doherty1*, K. Katsanos2, J. Burisch3, M. Allez4, K. Papamichael5, A. Stallmach6, R. Mao7, I. Prytz Berset8, J. Gisbert9, S. Sebastian10, J. Kierkuś11, L. Lopetuso12, E. Szymanska11, E. Louis13

Created: Thursday, 21 February 2019, 9:14 AM
DOP064: High rate of advanced neoplasia after detection of low-grade dysplasia in inflammatory bowel disease patients with primary sclerosing cholangitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ten Hove J.R.*1, Torres J.2, Castaneda D.2, Palmela C.2, Mooiweer E.1, Shah S.C.2, Colombel J.-F.2, Ullman T.2, Itzkowitz S.H.2, Oldenburg B.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP064: High rate of advanced neoplasia after detection of low-grade dysplasia in Inflammatory Bowel Disease patients with primary sclerosing cholangitis
Year: 2017
Source: ECCO'17 Barcelona
Authors: Ten Hove J.
Sclerosing Cholangitis, Colonoscopy, Dysplasia
Files: 1
DOP065: Less anti-infliximab antibody formation in paediatric Crohn's patients on concomitant immunomodulators
Year: 2016
Source: ECCO'16 DOP
Authors: Wolters V.
anti-TNF agents, therapeutic drug monitoring
Files: 1
DOP065: Less anti-infliximab antibody formation in paediatric Crohns patients on concomitant immunomodulators
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

H. Kansen1, P. van Rheenen2, R. Houwen1, W. Tjon A Ten3, G. Damen4, A. Kindermann5, J. Escher6, V. Wolters*1

Created: Friday, 22 February 2019, 9:49 AM